Market capitalization | $6.81m |
Enterprise Value | $470.00k |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 0.05 |
P/S ratio (TTM) P/S ratio | 0.79 |
P/B ratio (TTM) P/B ratio | 0.93 |
Revenue growth (TTM) Revenue growth | 100.35% |
Revenue (TTM) Revenue | $8.62m |
As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.
1 Analyst has issued a forecast Evoke Pharma, Inc.:
1 Analyst has issued a forecast Evoke Pharma, Inc.:
Sep '24 |
+/-
%
|
||
Revenue | 8.62 8.62 |
100%
100%
|
|
Gross Profit | 8.32 8.32 |
110%
110%
|
|
EBITDA | -5.90 -5.90 |
19%
19%
|
EBIT (Operating Income) EBIT | -5.90 -5.90 |
19%
19%
|
Net Profit | -6.15 -6.15 |
19%
19%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Evoke Pharma, Inc. is a pharmaceutical company, which engages in the development of drugs for the treatment of gastrointestinal disorders and diseases. It develops Gimoti, with promotility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women with diabetes mellitus. The company was founded by Matthew J. D'Onofrio, Cam L. Garner, Scott L. Glenn, and David A. Gonyer in January 2007 and is headquartered in Solana Beach, CA.
Head office | United States |
CEO | Matthew D'Onofrio |
Employees | 4 |
Founded | 2007 |
Website | www.evokepharma.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.